Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 123 Carcinoma, Hepatocellular 72 Neoplasms 48 Breast Neoplasms 48 Small Cell Lung Carcinoma 46 Lung Neoplasms 42 Triple Negative Breast Neoplasms 40 Colorectal Neoplasms 39 Melanoma 35 Urinary Bladder Neoplasms 33 Neoplasm Metastasis 31 Carcinoma, Transitional Cell 31 Carcinoma, Renal Cell 29 Ovarian Neoplasms 20 Uterine Cervical Neoplasms 19 Stomach Neoplasms 17 Squamous Cell Carcinoma of Head and Neck 17 Head and Neck Neoplasms 15 Prostatic Neoplasms 13 Liver Neoplasms 13 Glioblastoma 12 Solid Tumors 11 Recurrence 11 Sarcoma 10 Esophageal Neoplasms 10 Pancreatic Neoplasms 9 Lymphoma 9 Endometrial Neoplasms 9 Mesothelioma, Malignant 8 Kidney Neoplasms 8

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × atezolizumab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡